Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
Saturday, April 19, 2025Calidi Biotherapeutics Inc a clinicalstage biotechnology company pioneering targeted antitumor virotherapies announced today that the US Food and Drug Administration FDA has cleared its Investigational New Drug IND application for CLD
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
Thursday, April 17, 2025GSK plcis pleased that the Advisory Committee on Immunization Practices ACIP voted in favor of recommending the use of RSV vaccines including GSKs AREXVY Respiratory Syncytial Virus Vaccine Adjuvanted in adults aged who are at increased risk
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Wednesday, April 16, 2025Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel therapies across a range of cancers today announced completion of patient enrollment in the ongoing Phase CRDF trial evaluating onvansertib in comb...
Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia
Tuesday, April 15, 2025Cellenkos Inc a clinicalstage biotechnology company focused on developing allogeneic offtheshelf T regulatory Treg cell therapies for inflammatory disease areas of high unmet needs and autoimmune disorders today announced that the US Food and Drug Ad...
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
Tuesday, April 15, 2025Cyprumed GmbH a dedicated drug delivery company specializing in innovative oral peptide formulations and MSD tradename of Merck Co Inc Rahway NJ USA today announced that the companies have signed a NonExclusive License
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
Monday, April 14, 2025Rocheannounced today that the European Commission has approved Columvi glofitamab in combination with gemcitabine and oxaliplatin GemOx for the treatment of adult patients with relapsed or refractory RR diffuse large Bcell lymphoma
Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
Friday, April 11, 2025Biocon Biologics Ltd BBL a subsidiary of Biocon Ltd today announced that the US Food and Drug Administration US FDA has approved Jobevne bevacizumabnwgd a biosimilar Bevacizumab for intravenous use JOBEVNE a recombinant humanized
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
Friday, April 11, 2025Shuttle Pharmaceuticals Holdings Inc a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy RT today announced the filing of a key provisional patent applica...
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Thursday, April 10, 2025Context Therapeutics Inc a biopharmaceutical company advancing T cell engagers for solid tumors today announced that the first patient has been dosed in the Phase clinical trial of CT a mesothelin MSLN x CD T cell engaging TCE bispecific
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
Wednesday, April 09, 2025Catalyst Pharmaceuticals Inca commercialstage biopharmaceutical company focused on inlicensing developing and commercializing novel medicines for patients living with rare and difficulttotreat diseases today reported that its sublicensee in Canada
